Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy

International Journal of Colorectal Disease

Volumn 23, Issue 1, 2008, Pages 37-45

  Terzi, Cem ^a,b   Canda, Aras Emre ^a   Sagol, Ozgul ^a   Atila, Koray ^a   Sonmez, Devrim ^a   Fuzun, Mehmet ^a   Gorken, Ilknur B ^a   Oztop, Ilhan ^a   Obuz, Funda ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Ki 67; p53; Preoperative chemoradiotherapy; Radiosensitivity; Rectal cancer; Survivin

Indexed keywords

BIOCHEMICAL MARKER; FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; PROTEIN P53; SURVIVIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; TREATMENT OUTCOME; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36348931603     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-007-0376-x     Document Type: Article

References (64)

1. Minsky BD, Cohen AM, Kemeny N et al (1992) Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 10:79-84
2. Minsky BD, Cohen AM, Kemeny N et al (1993) The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 71:3486-3492
3. Marsh RD, Chu NM, Vauthey JN et al (1996) Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 78:217-225
4. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
5. Valentini V, Coco C, Picciocchi A et al (2002) Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674
6. Reerink O, Karrenbeld A, Plukker JT et al (2004) Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res 24:1217-1221
7. Theodoropoulos G, Wise WE, Padmanabhan A et al (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45:895-903
8. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P (2002) Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94:1121-1130
9. Ruo L, Tickoo S, Klimstra DS et al (2002) Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236:75-81
10. Wheeler JM, Dodds E, Warren BF et al (2004) Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: Correlation with rectal cancer regression grade. Dis Colon Rectum 47:2025-2031
11. Crane CH, Skibber JM, Feig BW et al (2003) Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97:517-524
12. Ammann K, Kirchmayr W, Klaus A et al (2003) Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum. Arch Surg 138:257-261
13. Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 23:1847-1858
14. Peeters KCMJ, van de Velde CJH, Leer JWH et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients. J Clin Oncol 23:6199-6206
15. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126-6131
16. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ (2006) Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 32:55-64
17. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43-49
18. Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584
19. Tiefenbacher U, Wenz F (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. Strahlenther Onkol 177:682-684
20. Rodel F, Hoffmann J, Grabenbauer GG et al (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178:426-435
21. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F (2003) Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55:1341-1347
22. Rodel F, Hoffmann J, Distel L et al (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881-4887
23. Sjödahl R (1997) Do we need adjuvant treatment for rectal cancer. Ann Med 29:91-93
24. Zaheer S, Pemberton JM, Farouk R et al (1998) Surgical treatment of adenocarcinoma of the rectum. Ann Surg 227:800-811
25. Sobin LH, Wittekind Ch (eds) (2002) International Union Against Cancer (UICC): TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
26. Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479-1482
27. Quirke P, Durdey P, Dixon MF, Williams NS (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical excision. Histopathological study of lateral tumor spread and surgical excision. Lancet 2:996-999
28. Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York
29. Begg CB, Carbone PP (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52:1986-1992
30. Gilcrease MZ, Truong L, Brown RW (1996) Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol 27(12):1355-1360
31. Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J colorectal Dis 12:19-23
32. Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garcia-Aguilar J (2000) Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 43:451-459
33. Fu CG, Tominaga O, Nagawa H et al (1998) Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 41(1):68-74
34. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P (2002) Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 100:131-135
35. Kandioler D, Zwrtek R, Ludwig C et al (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235:493-498
36. Lopez-Crapez E, Bibeau F, Thezenas S et al (2005) p53 status and response to radiotherapy in rectal cancer: A prospective analysis. Br J Cancer 92:2114-2121
37. Thompson LH, Humphrey RM (1970) Proliferation kinetics of mouse L-P59 cells irradiated with ultraviolet light: A time-lapse photographic study. Radiat Res 41(1):183-201
38. Tolmach LJ (1961) Growth patterns in x-irradiated HeLa cells. Ann N Y Acad Sci 95:743-757
39. Rau B, Sturm I, Lage H et al (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21:3391-3401
40. Rodel C, Grabenbauer GG, Papadopoulos T et al (2002) Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52:294-303
41. Key G, Becker MH, Baron B et al (1993) New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68:629-636
42. Schalzen T, Gerdes J (2002) The Ki-67 protein: From the known and the unknown. J Cell Physiol 182:311-322
43. Kim NK, Park JK, Lee KY et al (2001) p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 8:418-424
44. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
45. Peltenburg LT (2000) Radiosensitivity of tumor cells. Oncogenes and apoptosis. Q J Nucl Med 44:355-364
46. Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304
47. Shin S, Sung BJ, Cho YS et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117-1123
48. Monzo M, Rosell R, Felip E et al (1999) A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17:2100-2104
49. Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-1812
50. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134
51. Kato J, Kuwabara Y, Mitani M et al (2001) Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92-95
52. Kappler M, Kohler T, Kampf C et al (2001) Increased survivin transcript levels: An independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 95:360-363
53. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645-650
54. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074
55. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
56. Blagosklonny MV (2004) Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 23:2967-2975
57. Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721-729
58. Meyn RE, Stephens LC, Milas L (1996) Programmed cell death and radioresistance. Cancer Metastasis Rev 15:119-131
59. Meyn RE, Stephens LC, Ang KK et al (1993) Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 64:583-591
60. Abe T, Sakaguchi Y, Ohno S et al (2001) Apoptosis and p53 overexpression in human rectal cancer; relationship with response to hyperthermo-chemo-radiotherapy. Anticancer Res 21:2115-2120
61. Scott N, Hale A, Deakin M et al (1998) A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol 24:169-173
62. Rich TA, Sinicrope F, Stephens C et al (1996) Down staging of T3 rectal cancer after pre operative infusional chemoradiation is correlated with spontaneous apoptosis index and Bcl 2 staining. Int J Radiat Oncol Biol Phys 36:259
63. Smith FM, Reynolds JV, Kay EW et al (2006) COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 64:466-472
64. Li F, Yang J, Ramnath N, Javie MM, Tan D (2005) Nuclear and/or cytoplasmic expression of surviving: What is the significance. Int J Cancer 114:509-512